Stock Analysis
Eli Lilly & Co.LLY
P/E 41.95×· 5Y range 30.17–143.46×· bottom 22% of history
Sector: Healthcare · Industry: Drug Manufacturers - General
AnalystsStrong Buy38 analystsP/E 41.9× sits at the 22nd percentile of its 5.089664613278576-year history.
Cash covers 16% of debt · Q2 2026.
PMP Verdict
Strong business, attractive price
Strengths
- Growth100
- Profitability100
High-quality business at an attractive price.
Bull Case
- ✓Piotroski F-Score 7/9 — high earnings quality
- ✓Altman Z 7.5 — safe-zone balance sheet
- ✓ROE 78.8% — efficient capital deployment
- ✓Revenue CAGR 23.2% — durable top-line growth
- ✓Interest coverage 29.7× — debt well covered
What's happening with LLY
Profile
Strong growth, profitability and moat; valuation lags behind.
How is each axis scored?
- Valuation35/100 · Weak
- P/E vs own history (22th pct)20/25
- FCF yield (1.6%)5/25
- P/S (14.1x)5/25
- EV/EBIT (30.9x)5/25
- Growth100/100 · Strong
- Revenue CAGR (23.2%)25/25
- Net income CAGR (38.7%)25/25
- EPS CAGR 5Y (39.1%)25/25
- Fwd implied growth (59.6%)25/25
- Profitability100/100 · Strong
- ROIC (37.3%)25/25
- ROE (78.8%)25/25
- Net margin (33.5%)25/25
- Operating margin (47.4%)25/25
- Financial Health67/100 · Moderate
- Altman Z (7.49)25/25
- Current ratio (1.35)12/25
- Interest coverage (29.7x)25/25
- Net cash / debt (D/A 32%)5/25
- Quality61/100 · Moderate
- Piotroski F (7/9)22/25
- Beneish M (-1.79)12/25
- FCF conversion (68%)15/25
- Margin stability (σ 9.8%)12/25
- Moat80/100 · Strong
- ROIC >12% years (9/10 yrs)25/25
- Median gross margin (77.2%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst -0.9%)5/25
About Eli Lilly & Co.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Show more
Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Headquarters: INDIANAPOLIS, IN · Employees: 50,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
35DP/E (TTM)41.9xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 30.2x–143.5x · 22nd pct
P/FCF86.4xD
Grade D: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield1.6%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 0.0%–2.8% · 64th pct
P/S (TTM)14.05xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 7.4x–22.9x · 55th pct
EV/EBIT30.9xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 25.7x–120.1x · 9th pct
EV/Sales15.3xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E26.2xC
Grade C: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio33.04xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio1.34B
Grade B: FairFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield0.49%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio21.7%A
Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
100A+ROIC37.3%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE78.8%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA22.0%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin33.5%A
Grade A: HighNet Income / Revenue
Operating Margin47.4%A
Grade A: HighTTM EBIT / TTM Revenue
Gross Margin83.4%A
Grade A: PremiumGross Profit / Revenue
FCF Margin22.8%A
Grade A: HighFCF / Revenue
True FCF Margin22.0%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
100A+Revenue CAGR23.2%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR38.7%A
Grade A: HighCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)39.1%A
Grade A: HighCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth59.6%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-2.2%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income2.4%A
Grade A: LowStock-based comp/Net income. >30% = dilution risk
SBC / Revenue0.8%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
67BAltman Z-Score7.49A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.35xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio0.68xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage29.7xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt Repayment2.5yA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT1.2xA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity1.62xC
Grade C: MedDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.16xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
61BPiotroski F-Score7/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-1.79C
Grade C: Gray zoneEarnings manipulation risk. < -2.22 Safe
FCF Conversion68.1%C
Grade C: AverageFCF / Net Income
Margin Stability9.8%C
Grade C: AverageEBIT margin std deviation. Lower = stable
Capex / Revenue12.4%C
Grade C: AverageTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.66xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
LUCIANO JUAN R Filed | LUCIANO JUAN R | Grant / award | +14 | |
Fyrwald J Erik Filed | Fyrwald J Erik | Grant / award | +9 | |
Alvarez Ralph Filed | Alvarez Ralph | Grant / award | +11 | |
Sulzberger Gabrielle Filed | Sulzberger Gabrielle | Grant / award | +4 | |
Seymour Melissa Filed | Seymour Melissa | Gift | -12 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Dozier Eric Filed | Dozier Eric | Gift | -216 | |
Hernandez Edgardo Filed | Hernandez Edgardo | Gift | -13 | |
Jonsson Patrik Filed | Jonsson Patrik | SellOpen market sale | -6500 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
80AROIC >12% Years9/10 yrsA
Grade A: DurableShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)77.2%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor-0.9%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$29.97
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$9.57
Cash & short-term investments per share (Finnhub)
Book Value / Share$35.98
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$54.91B
Total debt obligations (short + long term)
Cash & Equiv.$8.95B
Cash and short-term investments
Net Debt$45.96B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$33.88B
Shareholders' equity (book value)
Asset / Liability1.31xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$1.12T
Current Market Capitalization
Beta0.42B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Eli Lilly & Co. (LLY)
Eli Lilly & Co. meets 7 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 7.49 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Revenue has compounded at roughly 23% annually, with net income growing about 39% per year — a strong growth profile. Eli Lilly & Co. converts about 23% of revenue into free cash flow — strong cash generation.
- Takes ~2.5 years to repay net debt from free cash flow.
- Eli Lilly & Co. posted a net loss in 1 of 10 available completed fiscal years (2016–2025).
- Return on equity of 78.8% is well above the market average.
See how LLY ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all LLY moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | Regular | 1,258.14 | +4.09% | 2.48 |
| Oct 15 | After-hours | 1,254.66 | +3.80% | 2.30 |
| Oct 14 | Regular | 1,207.66 | +3.53% | 2.54 |
| Oct 14 | After-hours | 1,208.19 | +3.57% | 2.57 |
| Oct 7 | After-hours | 1,188.37 | +2.67% | 2.17 |
Frequently Asked Questions about LLY
What is the current Eli Lilly & Co. (LLY) stock price?
LLY is trading at $1257.03 at the last market close, up 0.43% on the session. PreMarketPrice tracks LLY pre-market, intraday and after-hours prices.
Is LLY stock a buy right now?
PreMarketPrice's quantitative model rates Eli Lilly & Co.'s financial health at 67/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is LLY stock overvalued?
Eli Lilly & Co. trades at a trailing P/E of 41.9 and our valuation score rates it 35/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Eli Lilly & Co. report earnings?
No confirmed earnings date is currently scheduled for LLY. The Earnings section lists recent reports and updates as dates are announced.
What sector does Eli Lilly & Co. operate in?
Eli Lilly & Co. operates in the Healthcare sector, within the Drug Manufacturers - General industry. The Related Stocks section lists sector peers for comparison.
What does Eli Lilly & Co. do?
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology.
About Eli Lilly & Co. (LLY) Stock
Eli Lilly & Co. (LLY) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry. As of the latest update, Eli Lilly & Co. is trading at $1257.03, up 0.43% on the day with a market capitalization of $1.12 trillion. The financial health score for LLY is 67/100, which indicates good financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for LLY stock.
LLY Stock Analysis & Key Metrics
On PreMarketPrice, you can track Eli Lilly & Co. (LLY) across multiple dimensions:
- Pre-market price & movement: Real-time LLY stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for LLY with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Eli Lilly & Co. across multiple reporting periods.
- Financial health score: A composite score of 67/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for LLY.
- Sector peers: Compare LLY against 6 other healthcare stocks on key financial metrics.
Is LLY a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Eli Lilly & Co. (LLY) as an investment. The financial health score of 67/100 suggests good financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Eli Lilly & Co. (LLY) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.